DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
Castle Biosciences (Nasdaq: CSTL) has announced reaching a significant milestone of over 200,000 DecisionDx-Melanoma clinical test orders. The DecisionDx-Melanoma is a 31-gene expression profile test designed for patients with stage I-III cutaneous melanoma.
The test provides personalized risk assessment by analyzing tumor biology and clinicopathologic features to predict recurrence risk, metastasis potential, and sentinel lymph node positivity. Its clinical value is validated by more than 50 peer-reviewed publications and studies involving over 10,000 patient samples, demonstrating association with improved patient survival.
Castle Biosciences (Nasdaq: CSTL) ha annunciato di aver raggiunto un traguardo importante con oltre 200.000 ordini del test clinico DecisionDx-Melanoma. Il DecisionDx-Melanoma è un test basato sull'analisi di 31 geni, pensato per pazienti con melanoma cutaneo in stadio I-III.
Il test offre una valutazione personalizzata del rischio analizzando la biologia del tumore e le caratteristiche clinicopatologiche per prevedere il rischio di recidiva, il potenziale di metastasi e la positività dei linfonodi sentinella. Il suo valore clinico è confermato da più di 50 pubblicazioni peer-reviewed e da studi che coinvolgono oltre 10.000 campioni di pazienti, dimostrando un'associazione con un miglioramento della sopravvivenza dei pazienti.
Castle Biosciences (Nasdaq: CSTL) ha anunciado haber alcanzado un hito significativo con más de 200,000 pedidos del test clínico DecisionDx-Melanoma. El DecisionDx-Melanoma es un test que analiza la expresión de 31 genes, diseñado para pacientes con melanoma cutáneo en estadio I-III.
El test proporciona una evaluación personalizada del riesgo mediante el análisis de la biología tumoral y características clinicopatológicas para predecir el riesgo de recurrencia, el potencial de metástasis y la positividad de los ganglios linfáticos centinela. Su valor clínico está validado por más de 50 publicaciones revisadas por pares y estudios que involucran más de 10,000 muestras de pacientes, demostrando una asociación con una mejor supervivencia de los pacientes.
Castle Biosciences (나스닥: CSTL)는 20만 건 이상의 DecisionDx-Melanoma 임상 검사 주문이라는 중요한 이정표를 달성했다고 발표했습니다. DecisionDx-Melanoma는 1~3기 피부 흑색종 환자를 위해 설계된 31개 유전자 발현 프로필 검사입니다.
이 검사는 종양 생물학과 임상 병리학적 특성을 분석하여 재발 위험, 전이 가능성 및 감시림프절 양성 여부를 예측하는 맞춤형 위험 평가를 제공합니다. 그 임상적 가치는 50건 이상의 동료 검토 논문과 10,000건 이상의 환자 샘플을 포함한 연구들에 의해 입증되었으며, 환자 생존율 향상과의 연관성이 확인되었습니다.
Castle Biosciences (Nasdaq : CSTL) a annoncé avoir atteint un jalon important avec plus de 200 000 commandes du test clinique DecisionDx-Melanoma. Le DecisionDx-Melanoma est un test d'expression génique à 31 gènes conçu pour les patients atteints de mélanome cutané aux stades I à III.
Ce test fournit une évaluation personnalisée du risque en analysant la biologie tumorale et les caractéristiques clinicopathologiques afin de prédire le risque de récidive, le potentiel métastatique et la positivité des ganglions lymphatiques sentinelles. Sa valeur clinique est validée par plus de 50 publications évaluées par des pairs ainsi que par des études impliquant plus de 10 000 échantillons de patients, démontrant une association avec une amélioration de la survie des patients.
Castle Biosciences (Nasdaq: CSTL) hat einen bedeutenden Meilenstein mit über 200.000 Bestellungen des klinischen DecisionDx-Melanoma-Tests erreicht. Der DecisionDx-Melanoma ist ein 31-Gen-Expressionsprofil-Test, der für Patienten mit kutanem Melanom im Stadium I-III entwickelt wurde.
Der Test bietet eine personalisierte Risikobewertung, indem er die Tumorbiologie und klinisch-pathologische Merkmale analysiert, um das Risiko für Rezidive, Metastasierungspotential und Sentinel-Lymphknoten-Positivität vorherzusagen. Sein klinischer Wert wird durch mehr als 50 peer-reviewte Veröffentlichungen und Studien mit über 10.000 Patientproben bestätigt, die eine Verbindung zu einer verbesserten Patientenüberlebensrate zeigen.
- Milestone achievement of 200,000 DecisionDx-Melanoma test orders indicates strong market adoption
- Test validated by 50+ peer-reviewed publications and 10,000+ patient samples
- Clinical evidence shows association with improved patient survival
- None.
FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma.
“We are excited by this milestone, which we believe is a testament to our shared desire with the melanoma healthcare community to improve the lives of patients,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “With every DecisionDx-Melanoma test, we aim to enable clinicians to make more informed, more precise treatment decisions that can improve patient outcomes.”
Hear more from Maetzold and patients whose lives have been impacted by the DecisionDx-Melanoma test in this video.
By harnessing the genetic information within a patient’s tumor biology and incorporating traditional clinicopathologic features, DecisionDx-Melanoma is designed to stratify patient risk and provide personalized results regarding a patient's individual predicted risk of recurrence and/or metastasis and likelihood of sentinel lymph node positivity. DecisionDx-Melanoma’s clinical value is supported by more than 50 peer-reviewed publications, has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples.
For more information about DecisionDx-Melanoma, visit www.CastleBiosciences.com.
About DecisionDx-Melanoma
DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: DecisionDx-Melanoma’s ability to (i) provide comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma and (ii) help clinicians make more informed, more precise treatment decisions; and Castle’s ability to improve the lives of melanoma patients. The words “believe,” “can,” “could,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/922474ef-72a9-41fc-8ca8-b89137e201f9
FAQ
What milestone did Castle Biosciences (CSTL) achieve with DecisionDx-Melanoma test in April 2025?
How many peer-reviewed publications support DecisionDx-Melanoma test's clinical value?
What does the DecisionDx-Melanoma test analyze for melanoma patients?
Which stages of melanoma patients can use the DecisionDx-Melanoma test?
